Cargando…

Emerging agents and regimens for multiple myeloma

The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yang, Li, Yi, Gu, Huiyao, Dong, Mengmeng, Cai, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654052/ https://www.ncbi.nlm.nih.gov/pubmed/33168044 http://dx.doi.org/10.1186/s13045-020-00980-5

Ejemplares similares

Emerging agents and regimens for hepatocellular carcinoma
por: Zhu, Xiao-Dong, et al.
Publicado: (2019)

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
por: Chen, Qingxiao, et al.
Publicado: (2022)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

The NEDD4‐1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2019)

Innovative Agents in Multiple Myeloma
por: Faiman, Beth, et al.
Publicado: (2014)

Bone-targeted agents in multiple myeloma
por: Nishida, Hiroko
Publicado: (2018)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Emerging agents and regimens for polycythemia vera and essential thrombocythemia
por: Shallis, Rory M., et al.
Publicado: (2021)

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/β-Catenin Signaling Pathways
por: Wu, Xiuhua, et al.
Publicado: (2020)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways
por: Qu, Jianwei, et al.
Publicado: (2021)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Kinase inhibitors as potential agents in the treatment of multiple myeloma
por: Abramson, Hanley N.
Publicado: (2016)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

Multiple Myeloma Therapy: Emerging Trends and Challenges
por: Dima, Danai, et al.
Publicado: (2022)

New investigational drugs with single-agent activity in multiple myeloma
por: Rajan, A M, et al.
Publicado: (2016)

Activation of Coagulation by Lenalidomide-Based Regimens for the Treatment of Multiple Myeloma
por: Isozumi, Yu, et al.
Publicado: (2013)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma
por: Wang, Yu, et al.
Publicado: (2023)

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
por: Koiwai, Kimiko, et al.
Publicado: (2021)

Chromosomal instability and acquired drug resistance in multiple myeloma
por: Wang, Wang, et al.
Publicado: (2017)

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
por: Swan, Dawn, et al.
Publicado: (2019)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
por: Jung, Sung-Hoon, et al.
Publicado: (2016)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Front line treatment of elderly multiple myeloma in the era of novel agents
por: Venon, Marie-Dominique, et al.
Publicado: (2009)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies
por: Larsen, Jeremy T., et al.
Publicado: (2015)

Novel agents in the treatment of multiple myeloma: a review about the future
por: Naymagon, Leonard, et al.
Publicado: (2016)

Clinical characteristics and survival of patients with IgD multiple myeloma
por: Li, Yi, et al.
Publicado: (2021)

Liquid biopsy by analysis of circulating myeloma cells and cell-free nucleic acids: a novel noninvasive approach of disease evaluation in multiple myeloma
por: Li, Shuchan, et al.
Publicado: (2023)

Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
por: de Queiroz Crusoe, Edvan, et al.
Publicado: (2014)

Evolution of Treatment Regimens in Multiple Myeloma: A Social Network Analysis
por: Mahony, Helen, et al.
Publicado: (2014)

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2018)

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)
por: Zhong, Yuping, et al.
Publicado: (2023)

Microenvironment drug resistance in multiple myeloma: emerging new players
por: Di Marzo, Lucia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_oc8gj3a5jgkfhkpak8f2v0tp4q